|
|
Volumn 11, Issue 10, 2012, Pages 740-
|
|
Trial watch: Dual-acting combination meets heart failure end point
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID;
3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN;
ALDOSTERONE ANTAGONIST;
AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;
ANGIOTENSIN RECEPTOR ANTAGONIST;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
MEMBRANE METALLOENDOPEPTIDASE;
RENIN INHIBITOR;
SODIUM;
VALSARTAN;
AGE;
COMORBIDITY;
DIURESIS;
DRUG DOSE TITRATION;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG TOLERABILITY;
FOLLOW UP;
HEART EJECTION FRACTION;
HEART FAILURE;
HEART LEFT ATRIUM VOLUME;
HEART VOLUME;
HUMAN;
MEDICAL RESEARCH;
MORBIDITY;
MORTALITY;
NATRIURESIS;
NOTE;
OUTCOME ASSESSMENT;
PATHOPHYSIOLOGY;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RESEARCH SUBJECT;
SAMPLE SIZE;
TREATMENT OUTCOME;
VASODILATATION;
AMINOBUTYRATES;
ANGIOTENSIN RECEPTOR ANTAGONISTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG COMBINATIONS;
ENDPOINT DETERMINATION;
HEART FAILURE;
HUMANS;
TETRAZOLES;
|
|
EID: 84866920524
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3855 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
